Tempest Therapeutics
Open
$1.25
Prev. Close
$1.26
High
$1.26
Low
$1.25
Market Snapshot
$17.93M
-0.4
-19.46
4
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company is headquartered in Brisbane California, California and currently employs 4 full-time employees. The company went IPO on 2012-10-04. Its programs range from early research to the lead program, amezalpat, a pivotal study in first-line hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, is a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 (PGE2), a pathway implicated in multiple cancers. Its development strategy for TPST-1495 includes evaluation in familial adenomatous polyposis (FAP), a rare genetic disorder that increases the risk of gastrointestinal cancers. Its pipeline also includes TPST-2003, TPST-2206, TPST-3003, and TPST-3206. TPST-2003 is a new dual-targeting CD19/BCMA CAR-T asset. TPST-2206 is a dual-targeting CD70/CD70 CAR-T for renal cell carcinoma. TPST-3206 is an allogeneic dual-targeting CD70/CD70.
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company is headquartered in Brisbane California, California and currently employs 4 full-time employees. The company went IPO on 2012-10-04. Its programs range from early research to the lead program, amezalpat, a pivotal study in first-line hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, is a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 (PGE2), a pathway implicated in multiple cancers. Its development strategy for TPST-1495 includes evaluation in familial adenomatous polyposis (FAP), a rare genetic disorder that increases the risk of gastrointestinal cancers. Its pipeline also includes TPST-2003, TPST-2206, TPST-3003, and TPST-3206. TPST-2003 is a new dual-targeting CD19/BCMA CAR-T asset. TPST-2206 is a dual-targeting CD70/CD70 CAR-T for renal cell carcinoma. TPST-3206 is an allogeneic dual-targeting CD70/CD70.
Recently from Cashu
Tempest Therapeutics Unveils TP-145: A Promising New Drug in Immuno-Oncology
Tempest Therapeutics Advances in Immuno-Oncology with New Drug Candidate Tempest Therapeutics, a leading player in the field of immuno-oncology, announces a significant development in its pipeline wit…
Tempest Therapeutics Expands Oncology Portfolio with Acquisition of Dual-CAR T Programs
Tempest Therapeutics Expands CAR T-Cell Therapy Portfolio Through Strategic Acquisition Tempest Therapeutics Inc. has recently announced a pivotal acquisition that could reshape its strategic directio…
Tempest Therapeutics Acquires Dual-CAR T Programs to Strengthen Oncology Portfolio
Tempest Therapeutics Expands CAR T-Cell Therapy Portfolio with Strategic Acquisition Tempest Therapeutics Inc. strengthens its position in the oncology market by announcing an all-stock acquisition of…